Safety of Nebulized Epinephrine in Smoke Inhalation Injury.

Area of Science:

• Pediatric Burn Care
• Respiratory Medicine
• Pharmacology

Background:

• Smoke inhalation injury is a severe complication in pediatric burn patients.
• Current treatments for smoke inhalation injury have limitations.
• The safety of nebulized epinephrine in this population is not well-established.

Purpose of the Study:

• To evaluate the safety of nebulized racemic epinephrine as a therapy for smoke inhalation injury in severely burned children.
• To compare outcomes between standard care and standard care plus nebulized epinephrine.

Main Methods:

• Pilot study with 16 pediatric patients (7-19 years) with severe burns (>30% TBSA) and smoke inhalation injury.
• Randomized controlled trial comparing standard care (nebulized acetylcysteine, heparin, albuterol) with standard care plus nebulized epinephrine.
• Primary safety endpoints included death, chest pain, and cardiopulmonary hemodynamic changes.

Main Results:

• No deaths or adverse events were attributable to nebulized epinephrine administration.
• No significant differences were observed between groups in age, sex, burn size, ventilator days, pulmonary function, or cardiopulmonary fitness.
• Nebulized epinephrine was well-tolerated in this pediatric cohort.

Conclusions:

• Nebulized racemic epinephrine appears to be safe for treating pediatric patients with smoke inhalation injury.
• Further efficacy studies with larger patient cohorts are warranted.
• This pilot study provides a foundation for future investigations into epinephrine's therapeutic role.